Latest news with #RichardFrank
Newsweek
5 days ago
- Health
- Newsweek
Gen Z and Millennials Have Differing Views on Ozempic
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Gen Z and millennials have radically different views on GLP-1s like Ozempic and how much they want the weight loss and diabetes drugs regulated, according to a new report from GLP-1 prescription weight loss company Levity. While 40 percent of current and recent GLP-1 (glucagon-like peptide-1) users said the current regulations are fair, 28 percent want fewer rules and 22 percent said there should be more. But in the millennial age group, users tend to want less regulation, while Gen Z leaned toward more. Why It Matters GLP-1s, which are injectable drugs that mimic hormones to reduce blood sugar and promote weight loss, have skyrocketed in popularity in recent years. Popular products, including Ozempic, Mounjaro, Wegovy and Zephound, have been a game changer for many Americans who are obese or have type 2 diabetes. However, stricter FDA rules are now in effect, banning certain compounded GLP-1s and making it more difficult for many Americans to secure the drugs, especially if using it for weight loss reasons. Ozempic is medicine for adults with type 2 diabetes. Ozempic is medicine for adults with type 2 diabetes. Steve Christo - Corbis/Corbis via Getty Images What To Know The Gen Z and millennial response to the stricter FDA rules have been notably different, according to Levity. At 31 percent, millennials were the most likely to favor fewer GLP-1 regulations compared to 19 percent of the group who wanted more. Gen Z, meanwhile, favored stricter rules at 37 percent, while 32 percent wanted fewer. "Millennials are more likely to be prescribed a GLP-1 as compared to Gen Z; therefore, it is not surprising that millennials desire less regulation on these drugs," Richard Frank, MD, MHSA, and chief medical officer at Vida Health, told Newsweek. "Having said that, the regulatory environment surrounding compounded agents, in general, and compounded GLP-1s, specifically, is not as rigorous as it is for branded and generic drugs. Therefore, compounded drugs carry unknown risks that more regulated medications do not." Because semaglutide is no longer on the FDA shortage list, compounding it can carry legal risks. Already, the effects are being felt, as 17 percent of GLP-1 users said it has become harder to get their medication since the FDA tightened rules on compounded semaglutide, Levity reported. There was also a difference in how the generations viewed their use of the drugs. While 75 percent of GLP-1 users believed they'll still be on their treatment plan a year from now, Gen Z was the least likely to think so, at 58 percent. What People Are Saying Board-certified endocrinologist Dr. Caroline Messer told Newsweek: "Millennials, many of whom are now managing midlife weight and metabolic health concerns, may see GLP-1s as a practical tool and want fewer barriers. Gen Z, meanwhile, is generally more wary of long-term unknowns, hence leaning toward more safeguards. Broadly, Americans are divided but lean toward keeping current regulations." Richard Frank, MD, MHSA, and chief medical officer at Vida Health, told Newsweek: "From a business perspective, limiting access to compounded drugs when branded drugs are available protects the drug companies' patents. This protection provides the financial incentive for drug companies to develop innovative new therapies." What Happens Next The long-term effects of GLP-1 medication use are so far unclear. A recent study discovered a new link between taking GLP-1 drugs and elevated risk of pancreatitis and kidney conditions, including kidney stones. And GLP-1 medications have also been associated with a higher risk of digestive problems, including nausea, vomiting, diarrhea and even stomach paralysis in rare cases.
Associated Press
11-06-2025
- Business
- Associated Press
Haier TV and Total Sonics Announce Addition of Award-Winning Total Cal Auto Calibration Technology to Next Generation of Haier TVs
- Total Cal gives AV manufacturers a cost-efficient and easy-to-use system to improve the sound quality of their products in challenging acoustic environments - MILFORD, Mass., June 11, 2025 (SEND2PRESS NEWSWIRE) — Total Sonics® (a division of THAT Corporation®) is very pleased to announce they've come to agreement with global CE powerhouse Haier Multimedia on licensing Total Cal®, their innovative automatic room calibration system. Total Cal's groundbreaking approach both simplifies the room calibration process for consumers and keeps costs down for manufacturers. Using the homeowner's smart phone or tablet, or a calibrated USB microphone, this advanced technology easily guides the user through measurements of a products' audio performance in the room. Then in mere seconds, this room-response data is compared to the original frequency response of the product, used to generate a customized correction curve, and programmed into the product. The resultant sound quality is greatly improved: better clarity, tonal balance, and bass response. According to Total Sonics' Vice President, Timothy Brault, 'We are thrilled Haier's team of outstanding product development experts have seen fit to add Total Cal as a key feature in their product line.' Total Cal is just one part of the Total Technology suite of smart audio processing and calibration technologies, which also includes Total Sonics speaker optimization, Total Volume® automated loudness control, Total Surround® sound field expansion, Total Bass™ psychoacoustic bass processing, and the Total Immersion™ height virtualization technology we've developed in conjunction with Psy(x) Research. Innovations like Total Cal are a direct reflection of THAT Corporation's legacy of improving audio performance, going back over 40 years to THAT's predecessor, dbx® inc. With Total Cal, better sound in the home can now be accomplished at more affordable price points. For further information on Haier TVs and sound products or any of the Total Sonics suite of applications, please contact Richard Frank of Frank Marketing: C – 949-637-0700, e – [email protected] ABOUT TOTAL SONICS: Started by engineers of legendary dbx® professional and consumer audio products, Total Sonics has been improving sound in consumer electronics for over 40 years, and Total Sonics technology has been used in over one billion devices worldwide. Manufacturers turn to Total Sonics to deliver an improved audio experience to consumers at a low cost, without the need for additional hardware. Total Sonics makes audio processing software for TVs, soundbars, speakers, cell phones and tablets, and other consumer devices. Learn more: and ABOUT HAIER: Today Haier reaches the global marketplace. Thirty-five years ago, Haier started serving the Chinese market. Today Haier has spread all over Asia, Africa, Europe, North America and the Middle East, truly to all corners of the world. There are 10 R&D centers, 24 industrial parks, 66 marketing centers and 108 manufacturing plants in the world. New brands continue to join the Haier family, Aqua, Fischer Parker, GEA, Candy, have recently become members of the greater family of Haier brands. Learn more: THAT Corporation, Total Sonics, Total Volume, Total Surround, Total Cal, Total Immersion, Total Bass, Total Technology, and dbx-tv, and their respective logos, are trademarks or registered trademarks of THAT Corporation. Haier and its respective logo are trademarks or registered trademarks of Haier Group or its subsidiaries. dbx is a registered trademark of Harman International. IMAGE link for media: Image caption: Haier TV and Total Sonics Announce Addition of Award-Winning Total Cal Auto Calibration Technology to Next Generation of Haier TVs. NEWS SOURCE: Total Sonics Keywords: Electronics, Haier TV and Total Sonics, Total Cal, Haier TV, Total Sonics, room calibration, audio optimization, Total Technology suite, home audio improvement, AV news, consumer electronics, smart television, Total Technology suite of smart audio processing and calibration technologies, MILFORD, Mass. This press release was issued on behalf of the news source (Total Sonics) who is solely responsibile for its accuracy, by Send2Press® Newswire. Information is believed accurate but not guaranteed. Story ID: S2P126887 APNF0325A To view the original version, visit: © 2025 Send2Press® Newswire, a press release distribution service, Calif., USA. RIGHTS GRANTED FOR REPRODUCTION IN WHOLE OR IN PART BY ANY LEGITIMATE MEDIA OUTLET - SUCH AS NEWSPAPER, BROADCAST OR TRADE PERIODICAL. MAY NOT BE USED ON ANY NON-MEDIA WEBSITE PROMOTING PR OR MARKETING SERVICES OR CONTENT DEVELOPMENT. Disclaimer: This press release content was not created by nor issued by the Associated Press (AP). Content below is unrelated to this news story.
Business Wire
20-05-2025
- Health
- Business Wire
Vida Health Members Achieve Clinically Significant Weight Loss Without Relying on High-Cost Medications, As Only 16% of New Members Receive GLP-1s
SAN FRANCISCO--(BUSINESS WIRE)-- Vida Health, a virtual, personalized obesity care provider that helps patients manage obesity and related conditions, today announced outcomes from its Clinical Obesity Management Program, which demonstrate that most patients do not require expensive GLP-1s to achieve sustainable, significant weight loss. Data from more than 18,000 participants demonstrates that Vida's tailored treatment plans and commitment to responsible prescribing deliver better outcomes, lower costs, and immediate ROI for health plans and employers. Key findings include: Smart, cost-saving GLP-1 utilization: Only 16% of new members who have not been on a GLP-1 in the past year are prescribed a GLP-1. With Vida's thoughtful oversight, Vida only guides patients to GLP-1s when clinically appropriate and supports the rest of its members with effective, lower-cost alternatives. This leads to immediate cost savings for partners. With Vida, employers and health plans can avoid prescription costs up to $475 per member per month for those with obesity. Clinically significant weight loss, without high-cost medications: 1 in 3 members lose 5% of their baseline weight in just 90 days without a GLP-1, and 50% of those on anti-obesity medication alternatives see an equivalent 5% weight loss – demonstrating that effective outcomes do not always require high-cost therapies. In fact, 33% of members see success relying on behavior change alone. High medication adherence: Vida members have a 94% medication adherence rate among all medical weight loss members, which is nearly triple the average for GLP-1 users in the US. Vida's providers build strong relationships with members and use cognitive behavioral techniques to motivate meaningful lifestyle changes. Through medical nutrition therapy delivered by registered dietitians, members receive prescriptive nutritional guidance, nutritional support for managing medication side effects, and tools for long-term success. Physician oversight and personalized lifestyle coaching ensure ongoing progress, allowing for real-time adjustments to treatment plans and reinforcing behavior change, which drives better health outcomes, higher member satisfaction, and stronger ROI for GLP-1 therapy when needed. "With or without medication, we know that encircling each member with a supportive, integrated care team makes all the difference,' said Richard Frank, MD, Chief Medical Officer at Vida Health. 'Our latest outcomes data reinforces that treating the physical, mental, and emotional needs of each individual to find the right care pathway, which is often not GLP-1s, drives sustainable health outcomes while controlling costs." To learn more about Vida's Clinical Obesity Management program and the company's virtual approach to personalized obesity care, visit About Vida Health Vida Health is a virtual, personalized obesity care provider that helps patients manage obesity and related conditions like diabetes, high blood pressure, anxiety, and depression with evidence-based treatment. Vida's team of obesity medicine-certified physicians, registered dietitians, expert coaches, and licensed therapists take a whole-person approach leading to clinically meaningful body weight loss in one year. Practicing responsible prescribing, Vida supports patients, employers, and health plans by prioritizing proven behavior change and lifestyle interventions before introducing medications, ensuring that only those who really need anti-obesity medications receive them — helping to control costs. Employers and health plans avoid prescription costs up to $475 per member per month for those with obesity. Vida serves members in all 50 states and Washington D.C., offers services in both English and Spanish, and operates on a value-based pricing model, putting outcomes at the center of care. To learn more, visit
